START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

Trial Details

NCT ID
NCT05492682
Phase
PHASE1
Sponsor
Valo Therapeutics Oy
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • PeptiCRAd-1
  • Cyclophosphamide
  • Pembrolizumab
Locations (sample)
  • Frankfurt, Germany|49.68333,10.53333
  • Heidelberg, Germany|49.40768,8.69079
  • Tübingen, Germany|48.52266,9.05222
  • Candiolo, Italy|44.95858,7.59812
  • Milan, Italy|45.46427,9.18951

Key Eligibility Criteria

  • Written informed consent.
  • Male or female, ≥18 years of age.
  • Patients with any 1 of the following histologically confirmed tumors and who qualifies for new or continued CPI therapy and relapsing to/after stan…
  • Inoperable/metastatic cutaneous malignant melanoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →